INTRODUCTION AND OBJECTIVES:
Early and precise localization of lesions in men with recurrent prostate cancer facilitates treatment when tumors are small and amenable to localized therapy and may guide salvage therapy decisions.
18 F-Fluciclovine is approved for use in Europe and the USA for localization of metastases in patients with suspected recurrence of prostate cancer by positron emission tomography (PET). The prospective LOCATE trial assessed the impact of 18 F-fluciclovine PET/CT on the management of men with PSArecurrence after curative intent primary therapy and negative/equivocal standard imaging. Here, we use data from LOCATE to evaluate the detection rate (DR) of 18 F-fluciclovine PET/CT in men with prostate cancer recurrence with or without radical prostatectomy (RP).
METHODS: Eligible men (! 18 y; prior curative intent treatment of prostate cancer; recurrence based on rising PSA; negative/equivocal findings on conventional imaging) underwent 18 F-fluciclovine PET/CT according to standard protocol at one of 15 US centers. Scan findings were stratified according to patients' prior therapy and baseline characteristics.
RESULTS: Between June 2016 and May 2017, 213 evaluable patients (median PSA [ 1.00 ng/mL; median 54 months post-initial diagnosis) were enrolled. In total, 164/213 (77%) men had RP prior to enrollment. The table shows baseline characteristics and the 18 F-fluciclovine DR according to RP status. PSA levels ranged more widely among the prior RP group compared with the intact prostate group, although the intact prostate group had a higher median PSA.
18
F-Fluciclovine-avid lesions were found in 122 (57%) men, with a DR of 49% (81/164) in men with prior RP and 84% (41/49) in the intact prostate group. The overall DR was broadly proportional to the pre-scan PSA and ranged from 31% among those with a PSA < 0.5 ng/mL to 95% among patients with a PSA > 10 ng/mL. In the prior prostatectomy group, the DR ranged from 31% at PSA < 0.5 ng/mL to 95% at PSA > 10 ng/mL. CONCLUSIONS: In this cohort of men with PSA-recurrence but negative/equivocal standard imaging, the majority were shown to have one or more lesion by 18 F-fluciclovine PET/CT. The DR increased with increasing PSA and was higher among patients with intact prostate than those who had previously undergone RP. PSMA PET/CT has demonstrated superior sensitivity in detecting prostate cancer metastases compared to traditional staging modalities and seen a high degree of utilisation in the Australian setting. However, there is little data published on the role of PSMA PET/CT in detecting and diagnosing primary prostate cancer. We compared the accuracy of PSMA PET/CT to multiparametric MRI for the detection of clinically significant primary prostate cancer.
METHODS: A local prospective database (REDCap-Monash) was maintained on patients who underwent MRI in our group urology practice from July 2013 to December 2017. All patients who had an MRI for diagnosis of prostate cancer, subsequent transperineal biopsy, and a PSMA PET/CT for initial staging were included, with significant cancer being defined as greater than or equal to Gleason 3þ4[7 (ISUP Grade Group 2).
RESULTS: The database contained 2,283 patients who underwent prostate MRI. 239 patients subsequently underwent both biopsy and PSMA PET/CT. 202 biopsies (84.5%) showed significant cancer. Of the non-significant cancer cases, 21 (8.8%) revealed Grade Group 1 lesions and 16 (6.7%) were benign. For significant cancers, 189 PSMA PET/CT scans demonstrated local PSMA avidity in the prostate, compared to 174 positive (PIRADS 4 or 5) MRI scans. MRI detected fewer insignificant cancers, but resulted in more false negatives. Overall, sensitivity and specificity for PSMA PET/CT and MRI respectively were 93.6%, 64.9% and 87.1%, 70.3%.
CONCLUSIONS: In this highly-selected cohort of patients undergoing prostate MRI, transperineal biopsy and PSMA PET/CT for staging as part of clinical practice, PSMA PET/CT outperformed MRI in detecting clinically significant primary prostate cancer. It is proposed that PSMA PET may be used in both diagnosis of primary cancers and staging, although cost-effectiveness in this dual role warrants further investigation. Higher sensitivity achieved by PSMA PET/CT comes at the expense of detecting clinically insignificant disease, evidenced by higher false-positive rates. Furthermore, the soft-tissue resolution and anatomical detail is inferior to MRI.
